Clinical characteristics of the cohort of patients refractory to daratumumab
| . | All patients who were Dara refractory, n = 29 (median, range) . |
|---|---|
| Median age (y) | 64 (46-87) |
| R-ISS III (at diagnosis) (%) | 32 |
| High-risk cytogenetics (%) | 48 |
| Disease duration (y) | 4.9 (0.8-15.8) |
| Prior treatment lines | 5 (2-11) |
| Lenalidomide refractory (%) | 96 |
| Bortezomib refractory (%) | 83 |
| Pomalidomide refractory (%) | 72 |
| Carfilzomib refractory (%) | 69 |
| Daratumumab refractory (%) | 90 |
| Pentarefractory (%) | 42 |
| Time off Dara (y) | 0.7 (0.02-4.1) |
| . | All patients who were Dara refractory, n = 29 (median, range) . |
|---|---|
| Median age (y) | 64 (46-87) |
| R-ISS III (at diagnosis) (%) | 32 |
| High-risk cytogenetics (%) | 48 |
| Disease duration (y) | 4.9 (0.8-15.8) |
| Prior treatment lines | 5 (2-11) |
| Lenalidomide refractory (%) | 96 |
| Bortezomib refractory (%) | 83 |
| Pomalidomide refractory (%) | 72 |
| Carfilzomib refractory (%) | 69 |
| Daratumumab refractory (%) | 90 |
| Pentarefractory (%) | 42 |
| Time off Dara (y) | 0.7 (0.02-4.1) |
High-risk cytogenetics include deletion of chromosome 17p, translocations t(4;14) and t(14;16).
Dara, daratumumab; R-ISS, Revised MM International Staging System.